PKN3 is required for invasive prostate cell growth as assessed by 3D cell culture assays and in an orthotopic mouse tumor model by inducible expression of short hairpin RNA (shRNA). PKN3 may represent a target for therapeutic intervention in cancers that lack tumor suppressor PTEN function or depend on chronic activation of PI3K.
Wissing J, Jänsch L, Nimtz M et al. (2007). "Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry". Mol. Cell Proteomics6 (3): 537–47. doi:10.1074/mcp.T600062-MCP200. PMID17192257.
Shibata H, Oishi K, Yamagiwa A et al. (2001). "PKNbeta interacts with the SH3 domains of Graf and a novel Graf related protein, Graf2, which are GTPase activating proteins for Rho family". J. Biochem.130 (1): 23–31. doi:10.1093/oxfordjournals.jbchem.a002958. PMID11432776.
Oishi K, Mukai H, Shibata H et al. (1999). "Identification and characterization of PKNbeta, a novel isoform of protein kinase PKN: expression and arachidonic acid dependency are different from those of PKNalpha". Biochem. Biophys. Res. Commun.261 (3): 808–14. doi:10.1006/bbrc.1999.1116. PMID10441506.